Expect Spero Therapeutics (SPRO) to Seek Partnership for tebipenem - Cowen Reiterates Market Perform on Stock
Tweet Send to a Friend
Cowen analyst Ritu Baral reiterated a Market Perform rating on Spero Therapeutics (NASDAQ: SPRO), as the company announces it received ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
